(PHR) Phreesia - Overview
Stock: Scheduling, Registration, Payments, Check-In, Analytics
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 53.3% |
| Relative Tail Risk | -7.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.63 |
| Alpha | -73.45 |
| Character TTM | |
|---|---|
| Beta | 0.989 |
| Beta Downside | 0.701 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.97% |
| CAGR/Max DD | -0.46 |
Description: PHR Phreesia January 16, 2026
Phreesia Inc. (NYSE: PHR) operates a SaaS-based platform that streamlines patient intake, scheduling, payment, and clinical communication for U.S. and Canadian healthcare providers. Its product suite spans mobile-first solutions (Phreesia Mobile), on-site self-service hardware (Phreesia Pads and Arrival Kiosks), and a web dashboard that integrates insurance verification, point-of-sale payments, and post-visit collections.
Recent filings show Phreesia’s annual recurring revenue grew ~22 % YoY to $210 million in FY 2024, while its gross margin stabilized near 78 %, reflecting the high-margin nature of SaaS. The company’s growth is tied to broader sector drivers: accelerated digitization of patient workflows post-COVID-19, consolidation among health systems that favor enterprise-wide intake solutions, and rising demand for flexible payment options as consumer-direct billing expands. However, churn remains a material risk; the latest disclosed net-revenue retention hovers around 92 %, indicating modest upside from existing accounts.
For a deeper, data-driven look at Phreesia’s valuation assumptions and scenario analysis, the ValueRay platform provides a granular breakdown of forward cash-flow metrics and comparable peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: -5.38m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 12.08 > 1.0 |
| NWC/Revenue: 30.68% < 20% (prev 19.84%; Δ 10.84% < -1%) |
| CFO/TA 0.15 > 3% & CFO 61.4m > Net Income -5.38m |
| Net Debt (-102.9m) to EBITDA (26.4m): -3.89 < 3 |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.5m) vs 12m ago 6.22% < -2% |
| Gross Margin: 68.20% > 18% (prev 0.67%; Δ 6753 % > 0.5%) |
| Asset Turnover: 115.9% > 50% (prev 107.8%; Δ 8.09% > 0%) |
| Interest Coverage Ratio: -1.01 > 6 (EBITDA TTM 26.4m / Interest Expense TTM 2.24m) |
Altman Z'' -12.15
| A: 0.34 (Total Current Assets 240.9m - Total Current Liabilities 98.8m) / Total Assets 423.5m |
| B: -1.89 (Retained Earnings -800.5m / Total Assets 423.5m) |
| C: -0.01 (EBIT TTM -2.26m / Avg Total Assets 399.6m) |
| D: -7.76 (Book Value of Equity -800.2m / Total Liabilities 103.1m) |
| Altman-Z'' Score: -12.15 = D |
Beneish M -3.32
| DSRI: 0.80 (Receivables 88.3m/96.5m, Revenue 463.2m/405.1m) |
| GMI: 0.98 (GM 68.20% / 67.14%) |
| AQI: 0.90 (AQ_t 0.38 / AQ_t-1 0.42) |
| SGI: 1.14 (Revenue 463.2m / 405.1m) |
| TATA: -0.16 (NI -5.38m - CFO 61.4m) / TA 423.5m) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of PHR shares?
Over the past week, the price has changed by -9.16%, over one month by -29.23%, over three months by -45.22% and over the past year by -57.80%.
Is PHR a buy, sell or hold?
- StrongBuy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.6 | 134.7% |
| Analysts Target Price | 28.6 | 134.7% |
| ValueRay Target Price | 9.3 | -24.1% |
PHR Fundamental Data Overview February 04, 2026
P/S = 1.7193
P/B = 2.5276
Revenue TTM = 463.2m USD
EBIT TTM = -2.26m USD
EBITDA TTM = 26.4m USD
Long Term Debt = 3.35m USD (from longTermDebt, last quarter)
Short Term Debt = 6.20m USD (from shortLongTermDebt, last quarter)
Debt = 3.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.9m USD (from netDebt column, last quarter)
Enterprise Value = 693.5m USD (796.4m + Debt 3.48m - CCE 106.4m)
Interest Coverage Ratio = -1.01 (Ebit TTM -2.26m / Interest Expense TTM 2.24m)
EV/FCF = 16.54x (Enterprise Value 693.5m / FCF TTM 41.9m)
FCF Yield = 6.04% (FCF TTM 41.9m / Enterprise Value 693.5m)
FCF Margin = 9.05% (FCF TTM 41.9m / Revenue TTM 463.2m)
Net Margin = -1.16% (Net Income TTM -5.38m / Revenue TTM 463.2m)
Gross Margin = 68.20% ((Revenue TTM 463.2m - Cost of Revenue TTM 147.3m) / Revenue TTM)
Gross Margin QoQ = 68.40% (prev 67.90%)
Tobins Q-Ratio = 1.64 (Enterprise Value 693.5m / Total Assets 423.5m)
Interest Expense / Debt = 23.70% (Interest Expense 826.0k / Debt 3.48m)
Taxrate = 16.66% (854.0k / 5.12m)
NOPAT = -1.88m (EBIT -2.26m * (1 - 16.66%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 240.9m / Total Current Liabilities 98.8m)
Debt / Equity = 0.01 (Debt 3.48m / totalStockholderEquity, last quarter 320.3m)
Debt / EBITDA = -3.89 (Net Debt -102.9m / EBITDA 26.4m)
Debt / FCF = -2.45 (Net Debt -102.9m / FCF TTM 41.9m)
Total Stockholder Equity = 291.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.35% (Net Income -5.38m / Total Assets 423.5m)
RoE = -1.85% (Net Income TTM -5.38m / Total Stockholder Equity 291.3m)
RoCE = -0.77% (EBIT -2.26m / Capital Employed (Equity 291.3m + L.T.Debt 3.35m))
RoIC = -0.63% (negative operating profit) (NOPAT -1.88m / Invested Capital 300.7m)
WACC = 9.60% (E(796.4m)/V(799.9m) * Re(9.56%) + D(3.48m)/V(799.9m) * Rd(23.70%) * (1-Tc(0.17)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.50%
[DCF Debug] Terminal Value 63.33% ; FCFF base≈41.9m ; Y1≈27.5m ; Y5≈12.6m
Fair Price DCF = 4.90 (EV 192.4m - Net Debt -102.9m = Equity 295.3m / Shares 60.3m; r=9.60% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 90.22 | EPS CAGR: 139.3% | SUE: -0.29 | # QB: 0
Revenue Correlation: 98.14 | Revenue CAGR: 21.47% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.35 | Chg30d=-0.029 | Revisions Net=+0 | Analysts=8
EPS next Year (2027-01-31): EPS=1.50 | Chg30d=-0.060 | Revisions Net=+0 | Growth EPS=+28.9% | Growth Revenue=+15.1%